Since CD8+ T cell infiltration correlates with better survival probability in many cancers, our results suggest that CCL5hi macrophages also play a critical role in ESCC receiving ICBs plus chemotherapy, and CD68+Stat1+ cell abundance could be a potential biomarker for response to the combined therapy in patients with ESCC. This evidence concerns the gene CD68 and cancer.